EC approves Pfizer’s Multiple Myeloma Drug Elrexfio
Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have had at least three prior therapies.
Elrexfio is a ready-to-use B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy that has been shown to induce deep and durable responses. It has a manageable tolerability profile and is available for subcutaneous dosing.
The conditional marketing authorisation is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway, and follows European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation in October 2023.
[…]The post EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma appeared first on Pharmafile.
